Related Experiment Video
Updated: Jul 19, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
[Use of cabergoline in persisting Cushing's disease]
F Illouz1, S Dubois-Ginouves, S Laboureau
1Service d'Endocrinologie, CHU Hôtel Dieu, 4 rue Larrey, 49033 Angers cedex 01. frillouz@chu-angers.fr
Abstract:
Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors. It has also been reported effective for patients with hypercortisolism uncontrolled by conventional therapies. We describe the use of cabergoline in three patients with Cushing's disease, one of them presenting a silent ACTH-secreting pituitary tumor. Those patients underwent surgery and only one has been treated with radiation therapy. However persisting hypercortisolism motivated the use of cabergoline. We describe a decrease or a normalization in hypercortisolism; for one of the subjects, tumor growth seemed to be stopped. While cabergoline can induce a suppression of cortisol secretion or a corticotroph tumor shrinkage, the sites of action remain unclear.
Related Concept Videos
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Drugs for Treatment of Constipation-Predominant IBS

